159 related articles for article (PubMed ID: 30842182)
1. Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1.
Kasahara N; Sunaga N; Tsukagoshi Y; Miura Y; Sakurai R; Kitahara S; Yokobori T; Kaira K; Mogi A; Maeno T; Asao T; Hisada T
Anticancer Res; 2019 Mar; 39(3):1455-1461. PubMed ID: 30842182
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
3. The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy.
Jiang AG; Lu HY
J Chemother; 2015 Feb; 27(1):35-9. PubMed ID: 24716851
[TBL] [Abstract][Full Text] [Related]
4. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.
Kasahara N; Imai H; Naruse I; Tsukagoshi Y; Kotake M; Sunaga N; Kaira K; Maeno T; Asao T; Hisada T
Thorac Cancer; 2020 Aug; 11(8):2188-2195. PubMed ID: 32495520
[TBL] [Abstract][Full Text] [Related]
5. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer.
Ru CH; Zhuang YB
Comb Chem High Throughput Screen; 2018; 21(10):711-717. PubMed ID: 30686251
[TBL] [Abstract][Full Text] [Related]
7. Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer.
Yotsukura M; Ohtsuka T; Kaseda K; Kamiyama I; Hayashi Y; Asamura H
J Thorac Oncol; 2016 Aug; 11(8):1311-1318. PubMed ID: 27234603
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
9. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Mimae T; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Int J Clin Oncol; 2020 Jan; 25(1):74-81. PubMed ID: 31531785
[TBL] [Abstract][Full Text] [Related]
10. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y
J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260
[TBL] [Abstract][Full Text] [Related]
13. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.
Suh KJ; Kim SH; Kim YJ; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Cancer Immunol Immunother; 2018 Mar; 67(3):459-470. PubMed ID: 29204702
[TBL] [Abstract][Full Text] [Related]
14. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.
Chen D; Menon H; Verma V; Guo C; Ramapriyan R; Barsoumian H; Younes A; Hu Y; Wasley M; Cortez MA; Welsh J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31996395
[TBL] [Abstract][Full Text] [Related]
15. A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer.
Guisier F; Cousse S; Jeanvoine M; Thiberville L; Salaun M
Sci Rep; 2019 Nov; 9(1):16902. PubMed ID: 31729430
[TBL] [Abstract][Full Text] [Related]
16. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer.
Ni XF; Wu J; Ji M; Shao YJ; Xu B; Jiang JT; Wu CP
Asia Pac J Clin Oncol; 2018 Dec; 14(6):402-409. PubMed ID: 30178541
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
19. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Zhang Y; Chen S; Chen H; Li W
Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
